ArticleFrontiers in immunology2025
The subsets of blood circulating T-cells associated with the development and prognosis of coinfection in patients with critical COVID-19.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: A secondary bacterial infection, which has a high incidence in patients with critical coronavirus disease 2019 (COVID-19), has been proven to have an association with increased mortality. Adaptive immune responses have been detected in almost all COVID-19 cases. This study aimed to determine whether the levels of immune-inflammatory factors are associated with coinfection in patients with critical COVID-19. Methods: Patients with a confirmed critical severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection were enrolled in this single-center cohort study. Clinical data and venous blood samples were collected on the day of hospital admission. All patients were divided into two groups according to the presence of bacterial coinfection or absence of bacterial coinfection, which were then divided into two groups (survived group and deceased group) based on the outcome of the disease during hospitalization. Results: Patients with coinfection had a higher mortality rate (83.3% VS 50.0%, P<0.001) and longer hospital stays (25.15 VS 13.80d, P<0.001). We observed that patients who developed coinfection tended to have a significantly lower number of CD4+ T cells (121.19 VS 207.83cells/µL, P=0.001) and CD8+ T cells (79 VS 158cells/µL, P=0.006) and a higher proportion of CD4+CD8+ double-positive T (DPT) cells (3.66% VS 1.91%, P=0.011) on the day of hospital admission. The tests for inflammatory cytokines showed a higher level of IL-4 (0.99 VS 0.42pg/mL, P<0.001) and IL-6 (109.60 VS 63.59pg/mL, P=0.009) in coinfection group. And the multivariant analyses also revealed that CD4+ cell counts < 199.5cells/µL, CD8+ cell counts < 124.5cells/µL, IL4 > 0.535pg/mL, IL6 > 388.9pg/mL could be independent risk factors for coinfection. Moreover, in the coinfection group, we observed that the deceased patients had a lower level of total lymphocytes, T cells, and albumin. Conclusion: Our study found that lymphocyte subsets and cytokines play an important role in predicting bacterial coinfection in patients with critical COVID-19. Lower levels of CD4+ and CD8+ cells and higher level of IL4 and IL6 in patients on the day of admission were significantly correlated with the development of coinfection the following days in the hospital.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.